[{"indications": "Indications\u00a0short-term treatment of moderate to severe atopic\r\neczema (including flares) either unresponsive to, or in patients intolerant\r\nof conventional therapy in adults and children over 16 years; short-term\r\ntreatment of moderate to severe atopic eczema (including flares) unresponsive\r\nto conventional therapy in children over 2 years; prevention of flares\r\nin patients with moderate to severe atopic eczema and 4 or more flares\r\na year who have responded to initial treatment (for a maximum of 6\r\nweeks) with topical tacrolimus; see also notes above; other\r\nindications section 8.2.2", "name": "TACROLIMUS - PREPARATIONS FOR ECZEMA AND PSORIASIS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response", "TACROLIMUS"], "cautions": "Cautions\u00a0UV light (avoid excessive exposure to\r\nsunlight and sunlamps); alcohol consumption\r\n(risk of facial flushing and skin irritation)", "side-effects": "Side-effects\u00a0application-site reactions including rash, irritation,\r\npain and paraesthesia; herpes simplex infection, Kaposi\u2019s varicelliform\r\neruption; application-site infections; less commonly acne; also reported rosacea and skin malignancy", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/119636.htm", "doses": ["Short-term treatment, adult and child over 16 years initially\r\napply 0.1% ointment thinly twice daily until lesion clears (consider\r\nother treatment if eczema worsens or no improvement after 2 weeks);\r\nreduce to once daily or switch to 0.03% ointment if condition allows; child 2\u201316 years, initially apply 0.03% ointment\r\nthinly twice daily for up to 3 weeks (consider other treatment if\r\neczema worsens or if no improvement after 2 weeks) then reduce to\r\nonce daily until lesion clears"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless essential; toxicity\r\nin animal studies following systemic administration"}, {"indications": "Indications\u00a0prophylaxis of organ rejection in liver,\r\nkidney, and heart allograft recipients and allograft rejection resistant\r\nto conventional immunosuppressive regimens, see also notes above;\r\nmoderate to severe atopic eczema (section 13.5.3)", "name": "TACROLIMUS - CORTICOSTEROIDS AND OTHER IMMUNOSUPPRESSANTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.2 Corticosteroids and other immunosuppressants", "TACROLIMUS"], "cautions": "Cautions\u00a0monitor blood pressure, ECG (important: see Cardiomyopathy below), fasting blood-glucose\r\nconcentration, haematological and neurological (including visual)\r\nparameters, electrolytes, hepatic and renal function; monitor whole blood-tacrolimus trough concentration\r\n(especially during episodes of diarrhoea)\u2014consult local treatment\r\nprotocol for details; QT-interval prolongation; neurotoxicity; increased\r\nrisk of infections, malignancies, and lymphoproliferative disorders; avoid excessive exposure to UV light including sunlight; interactions: Appendix 1 (tacrolimus)Driving\u00a0May affect performance of\r\nskilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0nausea, vomiting, diarrhoea, constipation, dyspepsia,\r\nflatulence, bloating, weight changes, anorexia, gastro-intestinal\r\ninflammation, ulceration, and perforation, hepatic dysfunction, jaundice,\r\ncholestasis, ascites, bile-duct abnormalities, oedema, tachycardia,\r\nhypertension, haemorrhage, thromboembolic and ischaemic events, dyspnoea,\r\npleural effusion, parenchymal lung disorders, sleep disturbances,\r\ntremor, headache, peripheral neuropathy, mood changes, depression,\r\nconfusion, anxiety, psychosis, seizures, paraesthesia, dizziness,\r\nrenal impairment, renal failure, renal tubular necrosis, urinary abnormalities,\r\nhyperglycaemia, electrolyte disturbances (including hyperkalaemia,\r\nhypokalaemia, and hyperuricaemia), blood disorders (including anaemia,\r\nleucopenia, pancytopenia, and thrombocytopenia), arthralgia, muscle\r\ncramp, visual disturbances, photophobia, tinnitus, impaired hearing,\r\nalopecia, sweating, acne; less commonly paralytic\r\nileus, gastro-intestinal reflux disease, peritonitis, pancreatitis,\r\nheart failure, arrhythmia, cardiac arrest, cerebrovascular accident,\r\ncardiomyopathy (important: see Cardiomyopathy below),\r\npalpitation, respiratory failure, coma, speech disorder, amnesia,\r\nparalysis, influenza-like symptoms, encephalopathy, coagulation disorders,\r\nphotosensitivity, cataract, hypoglycaemia, dysmenorrhoea, hypertonia,\r\ndermatitis; rarely pericardial effusion, respiratory\r\ndistress syndrome, posterior reversible encephalopathy syndrome, dehydration,\r\nthrombotic thrombocytopenic purpura, blindness, toxic epidermal necrolysis,\r\nhirsutism; very rarely myasthenia, haemorrhagic cystitis,\r\nStevens-Johnson syndromeCardiomyopathy\u00a0Cardiomyopathy has been reported\r\nin children. Patients should be monitored by echocardiography for\r\nhypertrophic changes\u2014consider dose reduction or discontinuation if\r\nthese occur", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/217767.htm", "doses": ["See under preparations", "liver transplantation, starting 12 hours after transplantation, by mouth, 100\u2013200\u00a0micrograms/kg daily in 2 divided doses; child 300\u00a0micrograms/kg daily in 2 divided doses", "Renal transplantation, starting within 24 hours of transplantation, by mouth, 200\u2013300\u00a0micrograms/kg daily in 2 divided doses; child 300\u00a0micrograms/kg daily in 2 divided doses", "Heart transplantation with antibody induction (starting within\r\n5 days of transplantation) or without antibody induction (starting\r\nwithin 12 hours of transplantation), by mouth, 75\u00a0micrograms/kg\r\ndaily in 2 divided doses; child with\r\nantibody induction (starting within 5 days of transplantation), 100\u2013300\r\nmicrograms/kg daily in 2 divided doses; without antibody induction\r\n(starting within 12 hours of transplantation), 300\u00a0micrograms/kg daily\r\nin 2 divided doses as soon as clinically possible (8\u201312 hours after\r\ndiscontinuing intravenous infusion)", "Maintenance treatment, dose adjusted according to response and\r\nwhole blood concentration", "Rejection therapy, seek specialist advice"], "pregnancy": "Pregnancy\u00a0exclude before treatment; avoid unless potential\r\nbenefit outweighs risk\u2014risk of premature delivery, intra-uterine growth\r\nrestriction, and hyperkalaemia; toxicity in animal studies"}, {"indications": "Indications\u00a0prophylaxis of organ rejection in liver,\r\nkidney, and heart allograft recipients and allograft rejection resistant\r\nto conventional immunosuppressive regimens, see also notes above;\r\nmoderate to severe atopic eczema (section 13.5.3)", "name": "TACROLIMUS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.2 Corticosteroids and other immunosuppressants", "TACROLIMUS"], "cautions": "Cautions\u00a0monitor blood pressure, ECG (important: see Cardiomyopathy below), fasting blood-glucose\r\nconcentration, haematological and neurological (including visual)\r\nparameters, electrolytes, hepatic and renal function; monitor whole blood-tacrolimus trough concentration\r\n(especially during episodes of diarrhoea)\u2014consult local treatment\r\nprotocol for details; QT-interval prolongation; neurotoxicity; increased\r\nrisk of infections, malignancies, and lymphoproliferative disorders; avoid excessive exposure to UV light including sunlight; interactions: Appendix 1 (tacrolimus)Driving\u00a0May affect performance of\r\nskilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0nausea, vomiting, diarrhoea, constipation, dyspepsia,\r\nflatulence, bloating, weight changes, anorexia, gastro-intestinal\r\ninflammation, ulceration, and perforation, hepatic dysfunction, jaundice,\r\ncholestasis, ascites, bile-duct abnormalities, oedema, tachycardia,\r\nhypertension, haemorrhage, thromboembolic and ischaemic events, dyspnoea,\r\npleural effusion, parenchymal lung disorders, sleep disturbances,\r\ntremor, headache, peripheral neuropathy, mood changes, depression,\r\nconfusion, anxiety, psychosis, seizures, paraesthesia, dizziness,\r\nrenal impairment, renal failure, renal tubular necrosis, urinary abnormalities,\r\nhyperglycaemia, electrolyte disturbances (including hyperkalaemia,\r\nhypokalaemia, and hyperuricaemia), blood disorders (including anaemia,\r\nleucopenia, pancytopenia, and thrombocytopenia), arthralgia, muscle\r\ncramp, visual disturbances, photophobia, tinnitus, impaired hearing,\r\nalopecia, sweating, acne; less commonly paralytic\r\nileus, gastro-intestinal reflux disease, peritonitis, pancreatitis,\r\nheart failure, arrhythmia, cardiac arrest, cerebrovascular accident,\r\ncardiomyopathy (important: see Cardiomyopathy below),\r\npalpitation, respiratory failure, coma, speech disorder, amnesia,\r\nparalysis, influenza-like symptoms, encephalopathy, coagulation disorders,\r\nphotosensitivity, cataract, hypoglycaemia, dysmenorrhoea, hypertonia,\r\ndermatitis; rarely pericardial effusion, respiratory\r\ndistress syndrome, posterior reversible encephalopathy syndrome, dehydration,\r\nthrombotic thrombocytopenic purpura, blindness, toxic epidermal necrolysis,\r\nhirsutism; very rarely myasthenia, haemorrhagic cystitis,\r\nStevens-Johnson syndromeCardiomyopathy\u00a0Cardiomyopathy has been reported\r\nin children. Patients should be monitored by echocardiography for\r\nhypertrophic changes\u2014consider dose reduction or discontinuation if\r\nthese occur", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/217767.htm", "doses": ["See under preparations", "liver transplantation, starting 12 hours after transplantation, by mouth, 100\u2013200\u00a0micrograms/kg daily in 2 divided doses; child 300\u00a0micrograms/kg daily in 2 divided doses", "Renal transplantation, starting within 24 hours of transplantation, by mouth, 200\u2013300\u00a0micrograms/kg daily in 2 divided doses; child 300\u00a0micrograms/kg daily in 2 divided doses", "Heart transplantation with antibody induction (starting within\r\n5 days of transplantation) or without antibody induction (starting\r\nwithin 12 hours of transplantation), by mouth, 75\u00a0micrograms/kg\r\ndaily in 2 divided doses; child with\r\nantibody induction (starting within 5 days of transplantation), 100\u2013300\r\nmicrograms/kg daily in 2 divided doses; without antibody induction\r\n(starting within 12 hours of transplantation), 300\u00a0micrograms/kg daily\r\nin 2 divided doses as soon as clinically possible (8\u201312 hours after\r\ndiscontinuing intravenous infusion)", "Maintenance treatment, dose adjusted according to response and\r\nwhole blood concentration", "Rejection therapy, seek specialist advice"], "pregnancy": "Pregnancy\u00a0exclude before treatment; avoid unless potential\r\nbenefit outweighs risk\u2014risk of premature delivery, intra-uterine growth\r\nrestriction, and hyperkalaemia; toxicity in animal studies"}, {"indications": "Indications\u00a0prophylaxis of organ rejection in liver,\r\nkidney, and heart allograft recipients and allograft rejection resistant\r\nto conventional immunosuppressive regimens, see also notes above;\r\nmoderate to severe atopic eczema (section 13.5.3)", "name": "TACROLIMUS Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.2 Corticosteroids and other immunosuppressants", "TACROLIMUS", "Modified release"], "cautions": "Cautions\u00a0monitor blood pressure, ECG (important: see Cardiomyopathy below), fasting blood-glucose\r\nconcentration, haematological and neurological (including visual)\r\nparameters, electrolytes, hepatic and renal function; monitor whole blood-tacrolimus trough concentration\r\n(especially during episodes of diarrhoea)\u2014consult local treatment\r\nprotocol for details; QT-interval prolongation; neurotoxicity; increased\r\nrisk of infections, malignancies, and lymphoproliferative disorders; avoid excessive exposure to UV light including sunlight; interactions: Appendix 1 (tacrolimus)Driving\u00a0May affect performance of\r\nskilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0nausea, vomiting, diarrhoea, constipation, dyspepsia,\r\nflatulence, bloating, weight changes, anorexia, gastro-intestinal\r\ninflammation, ulceration, and perforation, hepatic dysfunction, jaundice,\r\ncholestasis, ascites, bile-duct abnormalities, oedema, tachycardia,\r\nhypertension, haemorrhage, thromboembolic and ischaemic events, dyspnoea,\r\npleural effusion, parenchymal lung disorders, sleep disturbances,\r\ntremor, headache, peripheral neuropathy, mood changes, depression,\r\nconfusion, anxiety, psychosis, seizures, paraesthesia, dizziness,\r\nrenal impairment, renal failure, renal tubular necrosis, urinary abnormalities,\r\nhyperglycaemia, electrolyte disturbances (including hyperkalaemia,\r\nhypokalaemia, and hyperuricaemia), blood disorders (including anaemia,\r\nleucopenia, pancytopenia, and thrombocytopenia), arthralgia, muscle\r\ncramp, visual disturbances, photophobia, tinnitus, impaired hearing,\r\nalopecia, sweating, acne; less commonly paralytic\r\nileus, gastro-intestinal reflux disease, peritonitis, pancreatitis,\r\nheart failure, arrhythmia, cardiac arrest, cerebrovascular accident,\r\ncardiomyopathy (important: see Cardiomyopathy below),\r\npalpitation, respiratory failure, coma, speech disorder, amnesia,\r\nparalysis, influenza-like symptoms, encephalopathy, coagulation disorders,\r\nphotosensitivity, cataract, hypoglycaemia, dysmenorrhoea, hypertonia,\r\ndermatitis; rarely pericardial effusion, respiratory\r\ndistress syndrome, posterior reversible encephalopathy syndrome, dehydration,\r\nthrombotic thrombocytopenic purpura, blindness, toxic epidermal necrolysis,\r\nhirsutism; very rarely myasthenia, haemorrhagic cystitis,\r\nStevens-Johnson syndromeCardiomyopathy\u00a0Cardiomyopathy has been reported\r\nin children. Patients should be monitored by echocardiography for\r\nhypertrophic changes\u2014consider dose reduction or discontinuation if\r\nthese occur", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200015.htm", "doses": ["See under preparations", "Renal transplantation, starting within 24 hours of transplantation, by mouth, 200\u2013300\u00a0micrograms/kg once daily in the morning", "child not recommended", "Name[Advagraf\u00ae (Astellas) ] Capsules, m/r, tacrolimus (as monohydrate)\r\n500\u00a0micrograms (yellow/orange), net price 50-cap pack = \u00a335.79; 1\u00a0mg\r\n(white/orange), 50-cap pack = \u00a371.59, 100-cap pack = \u00a3143.17; 3\u00a0mg\r\n(orange), 50-cap pack = \u00a3214.76; 5\u00a0mg (red/orange), 50-cap pack =\r\n\u00a3266.92. \r\n    Label:\r\n    23, 25, counselling, drivingNote\u00a0Tacrolimus is incompatible with PVCDose\u00a0liver transplantation, starting 12\u201318 hours after transplantation, by mouth, 100\u2013200\u00a0micrograms/kg once daily in the morningRenal transplantation, starting within 24 hours of transplantation, by mouth, 200\u2013300\u00a0micrograms/kg once daily in the morningRejection therapy, seek specialist advicechild not recommended"], "pregnancy": "Pregnancy\u00a0exclude before treatment; avoid unless potential\r\nbenefit outweighs risk\u2014risk of premature delivery, intra-uterine growth\r\nrestriction, and hyperkalaemia; toxicity in animal studies"}]